Sunday, December 16, 2007

It's Beginning to Look a Lot Like Solstice

Post below lifted from No Pasaran . See the original for links. Immediately below is the soft-porn actress chosen by the BBC to portray the Blessed Virgin.

Trapped in Beeb-istan: the Provisional Wing of the PC left has finally found a way to get into the Christmas spirit.

Former Brookside babe Jennifer Ellison is to star in a new BBC adaptation of the Nativity story. The new show will be broadcast live on BBC Three on December 16th and will see Ellison playing the part of a pregnant Mary who is fighting to stop her asylum-seeker boyfriend Joseph from being deported.

Further, the Ho Ho Hosebag will be sexing-up the dumbing-down of the greatest story ever told:

Jennifer Ellison will don a silver catsuit to play an angel in the BBC's new adaptation of the Nativity story.

I suppose the point they're making really is that there is no reason to become a citizen since the only notion they now have of what a citizenship is feeling perpetually guilty about your very being. That's sure to bring the brain-trust knocking on their doors, and that forgiveness and salvation are available with a Scheisster and paperwork sent to the Home Office.

This is the same BBC that refers to any other nations newcomers as immigrants, but otherwise as "migrants" only when referring to a foreigner in the UK, legally there or not, seeking citizenship or not.

Conservative British Muslim tells some home truths

The Conservative peer who helped negotiate the release of the primary school teacher jailed in Sudan for allowing her pupils to name a teddy bear Mohamed attacked her fellow British Muslims today for their "victim culture". Baroness Warsi, a Conservative spokeswoman on community cohesion, also criticised Labour for its "patronage politics" and for having encouraged the "divisive concept" of multiculturalism.

Lady Warsi, 36, born to Pakistani parents in Dewsbury, Yorkshire, is the youngest member of the House of Lords. She came to public notice earlier this month when she was asked by Lord Ahmed, a Labour peer, to accompany him to Sudan to mediate the release of Gillian Gibbons, who had been jailed for insulting Islam.

The situation in Sudan had been extraordinary and "thankfully" could never happen in the UK, Lady Warsi told a race relations conference in London this morning. "And yet it had echoes of situations we do get in Britain," she added, describing how cultural misunderstandings had exacerbated a local problem, which had then been taken up by religious and political leaders "busting for a fight". "These three factors - local disputes, cultural misunderstandings and hardliners stirring up trouble - these are very familiar to us in Britain," she said.

It was entirely possible to respect religious doctrine while living within a democracy, Lady Warsi said. To do so successfully, it was crucial to make the distinction between religious faith and cultural practice. "This distinction is vital because there is a growing tendency among some people to describe what are really social expectations - and often pretty dubious ones - as religious requirements.

"...British Muslims have the foremost responsibility here," she added. "As long as the Muslim community remains in a victim culture, a siege mentality, they allow others to control the debate.

"When it comes to Islam, the majority of Muslims understand the difference between culture and religion. It's not for others to tell Muslims what is and isn't Islam. It's for the community, and in that I include myself, to expound the truth about our faith - not let others interpret it for us. It is for us to be the change - not let others impose it on us."

Lady Warsi, who is thought to be the first British Muslim to serve in either the Cabinet or Shadow Cabinet, pointed out that she gone to Sudan with a Labour peer and had been proud to be part of a bipartisan effort where party differences did not matter. "But this is not to say that there are no differences between the parties when it comes to cohesion at home," she added.


New breast cancer drug offers long protection with fewer side-effects

Get it while you can. Good drugs often get taken off the market beciause of very rare apparent adverse side-effects. A drug with no side-effects will have no main effects

A new drug for breast cancer is better than the treatments that are already widely available and can prevent the disease returning for up to eight years, researchers say. Anastrozole, marketed as Arimidex, is thought to have set a new bench-mark for treating early stage breast cancer in postmenopausal women whose disease is fuelled by oestrogen.

The latest study confirms that the drug produces better results than tamoxifen, which has been a preferred treatment for more than 20 years. The study, published in The Lancet Oncology medical journal, suggests that the drug continues to work even after a patient stops taking it, with a greater chance that tumours will not return or spread.

Although tamoxifen is credited with saving the lives of 20,000 women since the 1980s, it is estimated that 23,000 new breast cancer patients a year could benefit from anastrozole and related drugs, known as aromatase inhibitors.

Anastrozole was approved for use on the NHS in August and has been prescribed to patients with breast cancer since November. Continuing trials are also investigating whether the treatment should be offered as a preventive therapy to women whose genes put them at particular risk of developing the disease. About four in five of the 41,000 women found to have breast cancer each year have passed the menopause and 70 per cent of these have cancers that are exacerbated by oestrogen.

Anastrozole acts by cutting the level of oestrogen circulating in the blood-stream, reducing the cancer risk in so-called receptor-positive cancers. The study looked at the safety and effectiveness of anastrozole compared with tamoxifen, which is sold as Nolvadex, Istubal and Valodex. Researchers followed the progress over five years of postmenopausal women with hormone-sensitive early breast cancer who were randomly assigned to either treatment or a combination of the two.

In a previous study, the chances of surviving for more than 68 months (5½ years) were 15 per cent greater for those on anastrozole than for those taking tamoxifen. In addition, the amount of time that passed before the breast cancer recurred rose by 25 per cent, and there was less cancer spread.

In the latest update on the trial after 100 months (just over eight years), researchers noted that the benefits of anastrozole were maintained even after the treatment was completed. Furthermore, the differences between the two groups in the time it took for the cancer to recur, if it did, increased. The study also suggested that there was no significant difference in the threat of heart disease between the treatment groups – an area of previous concern. Although anastrozole can cause loss of bone density and increase the risk of fractures in women taking the drug, a common osteoporosis drug can help to prevent this side-effect, experts say.

The authors concluded: “The findings of this report extend the previously reported superior efficacy of anastrozole over tamoxifen at 68 months of follow-up to 100 months. We also show a carry-over benefit for recurrence in the hormone-receptor-positive population which is larger than that shown for tamoxifen.”

Margaret Coulton, 61, a retired office worker from Hesketh Bank, near Preston, had surgery to remove a tumour in September 2003 and has been taking anastrozole for nearly four years as part of a clinical trial after initially taking tamoxifen. Switching to anastrozole banished the symptoms she was getting, such as hot flushes, tiredness and nausea, and allowed her to stop taking drugs for depression, another side-effect of tamoxifen, she said.

Cancer charities welcomed the latest results. Emma Pennery, a nurse consultant at Breast Cancer Care, said: “From our contact with hundreds of people living with breast cancer we know that many will be delighted to see this latest evidence of success.”


Yes Minister: British bureaucrats help PRESERVE freedom of information: "At the turn of the year, Government forces, led by Lord Falconer of Thoroton, then Lord Chancellor, appeared determined to press ahead with new rules that would stop the media and campaign groups from making costly and embarrassing requests for information. New documents released under the Freedom of Information Act now provide a clearer understanding of why the Government got cold feet. Responses to its own consultation paper published last year include submissions from FOI officers who show themselves to be less than enthusiastic about the idea of “blanket aggregation”, whereby a financial cap would be put on the amount of money that could be spent on complying with FOI requests made by individuals from within the same organisation. Government agencies were even less enthusiastic. In its detailed response, Transport for London noted that the consultation paper did not present any evidence that “burdensome FOI requests are a significant or extensive problem outside of central government”. [Embarrassing political info is no skin off the bureaucrats' nose but processing requests does provide jobs for them]

Britain: Muslim car thieves: "Five members of a multimillion-pound "car-ringing" gang, who stole luxury cars after trawling expensive areas of London were sentenced yesterday . The 34 stolen vehicles included Porsches, Mercedes, BMWs, Range Rovers, Toyota Land Cruisers and an Aston Martin. Southwark Crown Court was told that the thieves videoed themselves at the wheel of high-powered cars on their mobile phones. One clip showed 21-year-old Yusef Kaduji behind the wheel of a Mercedes McLaren worth 300,000 pounds. Imran Ganchi, a father-of-two from Ilford, who masterminded the operation, was jailed for six years; Kaduji, from East London, got two years; Hameed Nawaz, 31, of Luton, received three years; and Shazad Hussain, 31, of Mosely, Birmingham, four years.Shakeel Shoukat, 21, also of Forest Gate, was given a 12-month sentence suspended for two years."

No comments: